Skip to main content

Advertisement

SpringerLink
Log in

Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies

  • Neuro-oncology (GJ Lesser, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Referring to any central nervous system (CNS) involvement with preceding or concurrent systemic disease, secondary CNS lymphoma (SCNSL) lacks a clear standard of care and historically carries a very poor prognosis. Aggressive histologies predominate, most notably diffuse large B cell lymphoma (DLBCL), with higher relative frequency in Burkitt lymphoma but lower absolute incidence. Therapeutic strategies commonly feature intensive CNS-penetrant chemotherapy, including methotrexate, cytarabine, and others. Combination regimens, novel targeted agents, and cellular therapy considerations are reviewed, noting that patients with SCNSL are often excluded from clinical trials and dedicated SCNSL studies are historically limited. Given these challenges, there has been renewed attention on CNS prophylaxis as well as strategies for early CNS detection. Prophylaxis is standard of care in Burkitt lymphoma, whereas its role in DLBCL and related histologies is increasingly unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zing N, Fischer T, Federico M, Chiattone C, Ferreri AJM. Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas. Crit Rev Oncol Hematol. 2021;167:103496. https://doi.org/10.1016/J.CRITREVONC.2021.103496.

    Article  PubMed  Google Scholar 

  3. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021;137(3):374-386. https://doi.org/10.1182/blood.2020006926. These studies highlight key real-world data in Burkitt lymphoma across a large sampling of institutions, including updated estimates on CNS involvement and the importance of intensified regimens in these patients whenever possible over R-EPOCH.

  4. Zayac AS, Evens AM, Danilov A, et al. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multi-center cohort study. Haematologica. Published online February 4, 2021. https://doi.org/10.3324/haematol.2020.270876. These studies highlight key real-world data in Burkitt lymphoma across a large sampling of institutions, including updated estimates on CNS involvement and the importance of intensified regimens in these patients whenever possible over R-EPOCH.

  5. Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, et al. Burkitt lymphoma international prognostic index. J Clin Oncol. 2021;39(10):1129–38. https://doi.org/10.1200/JCO.20.03288.

    Article  CAS  PubMed  Google Scholar 

  6. Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis--a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk. 2015;15(8):451–7. https://doi.org/10.1016/j.clml.2015.02.026.

    Article  PubMed  Google Scholar 

  7. El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195–203. https://doi.org/10.1016/j.ejca.2016.12.029.

    Article  PubMed  Google Scholar 

  8. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(5):1046–52. https://doi.org/10.1093/annonc/mdp432.

    Article  CAS  Google Scholar 

  9. Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ, Inwards DJ Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88(1):154-161. http://www.ncbi.nlm.nih.gov/pubmed/10618618. Accessed 29 July 2018.

  10. Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96(7):1002–7. https://doi.org/10.3324/haematol.2011.041277.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413-423. https://doi.org/10.1182/BLOOD.2021012888. Our own study highlights the lack of clear difference between administration routes using MTX-based prophylaxis, the uncertainties in overall efficacy with CNS prophylaxis, and the need for prospective evaluation to more definitively answer this question.

  12. Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81. https://doi.org/10.1182/blood-2015-10-673236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–6. https://doi.org/10.1200/JCO.2015.65.6520.

    Article  CAS  PubMed  Google Scholar 

  14. Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919–26. https://doi.org/10.1182/blood-2018-07-862862.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. https://doi.org/10.1182/blood-2003-05-1545.

    Article  CAS  PubMed  Google Scholar 

  16. El-Khouly FE, van Vuurden DG, Stroink T, et al. Effective drug delivery in diffuse intrinsic pontine glioma: a theoretical model to identify potential candidates. Front Oncol. 2017;7(OCT). https://doi.org/10.3389/FONC.2017.00254.

  17. Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF. Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: update of the literature. Clin Pharmacokinet. 2016;55(3):297–311. https://doi.org/10.1007/S40262-015-0319-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Korfel A. A focus on pharmacotherapy for primary central nervous system lymphoma. Expert Rev Hematol. 2015;8(5):559–62. https://doi.org/10.1586/17474086.2015.1066672.

    Article  CAS  PubMed  Google Scholar 

  19. Slevin M, Piall E, Aherne G, Harvey V, Johnston A, Lister T. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983;1(9):546-551. https://doi.org/10.1200/JCO.1983.1.9.546.

  20. Ferreri AJM, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist. 2011;16(3):336–41. https://doi.org/10.1634/THEONCOLOGIST.2010-0361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466–8. https://doi.org/10.1182/blood-2002-06-1636.

    Article  CAS  PubMed  Google Scholar 

  22. Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235–9. https://doi.org/10.1212/WNL.0000000000000593.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57–68. https://doi.org/10.1016/j.ejca.2018.01.073.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9. https://doi.org/10.1200/JCO.2013.50.4910.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10. https://doi.org/10.1182/blood-2014-10-604561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lugtenburg PJ, de Nully Brown P, van der Holt B, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). J Clin Oncol. Published online July 30, 2020:JCO.19.03418. https://doi.org/10.1200/jco.19.03418

  27. Fujimoto T. Pharmacokinetics of intrathecal chemotherapy and clinical problems. Gan To Kagaku Ryoho. 11(8):1536-1542.

  28. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745–51. https://doi.org/10.1182/blood-2012-07-440974.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gilbar PJ, Carrington CV. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags. J Oncol Pharm Pract. 2006;12(2):113–8. https://doi.org/10.1177/1078155206070448.

    Article  PubMed  Google Scholar 

  30. Zelenetz AD. NCCN guidelines: B-cell lymphomas. Version 5.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 10 Nov 2021.

  31. Masaki Y, Miki M, Sun Y, Nakamura T, Iwao H, Nakajima A, Kurose N, Sakai T, Jin ZX, Sawaki T, Kawanami T, Fujita Y, Tanaka M, Fukushima T, Hirose Y, Umehara H. High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma. Int J Hematol. 2011;93(6):720–6. https://doi.org/10.1007/S12185-011-0848-1.

    Article  CAS  PubMed  Google Scholar 

  32. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian BA, Baiocchi RA, Maddocks K, Sawalha Y. Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas. Blood Adv. 2022;6(2):460–72. https://doi.org/10.1182/BLOODADVANCES.2021005999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y. Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study. Ther Adv Hematol. 2022;13:1–16. https://doi.org/10.1177/20406207221112900.

    Article  Google Scholar 

  34. Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer. 2017;123(22):4314–24. https://doi.org/10.1002/cncr.30965.

    Article  PubMed  Google Scholar 

  35. Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematol Oncol. 2017;35(4):497–503. https://doi.org/10.1002/HON.2342.

    Article  CAS  PubMed  Google Scholar 

  36. Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–27. https://doi.org/10.1016/S2352-3026(16)00036-3.

    Article  PubMed  Google Scholar 

  37. Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, Palmer E, Albertson T, Ferry JA, Arrillaga-Romany IC. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8):783–4. https://doi.org/10.1056/NEJMc1704610.

    Article  PubMed  Google Scholar 

  38. Frigault MJ, Maus MV, Dietrich J, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–6. https://doi.org/10.1182/blood.2019001694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet (London, England). 2022;399(10343):2294-2308. https://doi.org/10.1016/S0140-6736(22)00662-6.

  40. Ollila TA, Kurt H, Waroich J, Vatkevich J, Sturtevant A, Patel NR, Dubielecka PM, Treaba DO, Olszewski AJ. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. Blood. 2021;137(8):1120–4. https://doi.org/10.1182/blood.2020007236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833-843.e5. https://doi.org/10.1016/J.CCELL.2017.04.012.

  42. Rusconi C, Cheah CY, Eyre TA, Tucker DL, Klener P, Gine E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer R, Pagani C, Dlugosz- Danecka M, Mocikova H, van Meerten T, Cencini E, Marín-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. Published online July 5, 2022. https://doi.org/10.1182/BLOOD.2022015560.

  43. Renaud L, Bossard JB, Carpentier B, Terriou L, Cambier N, Chanteau G, Escure G, Tilmont R, Barbieux S, Wemeau M, Hieulle J, Boyle EM, Morschhauser F. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol. 2021;107(3):370–3. https://doi.org/10.1111/EJH.13667.

    Article  CAS  PubMed  Google Scholar 

  44. Lewis KL, Chin CK, Manos K, Casey J, Hamad N, Crawford J, Ho SJ, Issa S, Grigg A, Wood P, Gandhi MK, do B, Nastoupil L, Hawkes EA, Cheah CY. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. Br J Haematol. 2021;192(6):1049–53. https://doi.org/10.1111/BJH.16946.

    Article  CAS  PubMed  Google Scholar 

  45. Houillier C, Chabrot CM, Moles-Moreau MP, Willems L, Ahle G, Waultier-Rascalou A, Fornecker LM, Hoang-Xuan K, Soussain C. Rituximab-lenalidomide-ibrutinib combination for relapsed/refractory primary CNS lymphoma: a case series of the LOC Network. Neurology. 2021;97(13):628–31. https://doi.org/10.1212/WNL.0000000000012515.

    Article  CAS  PubMed  Google Scholar 

  46. Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436–45. https://doi.org/10.1182/blood-2018-09-875732.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Roschewski M, Lionakis MS, Melani C, et al. Dose-adjusted Teddi-R induces durable complete remissions in relapsed and refractory primary CNS lymphoma. Blood. 2018;132(Supplement 1):4195-4195. https://doi.org/10.1182/BLOOD-2018-99-112184.

  48. Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595–607. https://doi.org/10.1182/bloodadvances.2017014845.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–88. https://doi.org/10.1016/S1470-2045(20)30225-4.

    Article  CAS  PubMed  Google Scholar 

  50. Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Br J Haematol. 2019;187(2):185-194. https://doi.org/10.1111/bjh.16070. These studies critically question the efficacy of stand-alone intrathecal prophylaxis. While not definitive, this question is unlikely to be answered more directly or conclusively in the coming years and these results have shifted practice.

  51. Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica. 2020;105(7):1914-1924. https://doi.org/10.3324/haematol.2019.229948. These studies critically question the efficacy of stand-alone intrathecal prophylaxis. While not definitive, this question is unlikely to be answered more directly or conclusively in the coming years and these results have shifted practice.

  52. Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283–90. https://doi.org/10.1002/cncr.25278.

    Article  PubMed  Google Scholar 

  53. Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, Cwynarski K, McKay P. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Adv. 2020;4(15):3586–93. https://doi.org/10.1182/bloodadvances.2020002421.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139(16):2499–511. https://doi.org/10.1182/BLOOD.2021014506.

    Article  CAS  PubMed  Google Scholar 

  55. Lewis KL, Jakobsen LH, Villa D, et al. High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-Cell lymphoma: an international retrospective study of 2300 high-risk patients. Blood. 2021;138(Supplement 1):181-181. https://doi.org/10.1182/BLOOD-2021-146737. Addition of prophylactic HD-MTX did not affect incidence of CNS relapse in this very large retrospective analysis. At time of this writing, only the published abstract was available for review.

  56. Mutter JA, Alig S, Lauer EM, et al. Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS lymphoma. Blood. 2021;138(Supplement 1):6-6. https://doi.org/10.1182/BLOOD-2021-149644. These two studies highlight important advances in early detection of CNS lymphoma, as well as limitations in what is currently known using commercially available techniques.

  57. Olszewski AJ, Chorzalska AD, Petersen M, et al. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. Blood Adv. 2021;5(24):5525-5535. https://doi.org/10.1182/BLOODADVANCES.2021004512. These two studies highlight important advances in early detection of CNS lymphoma, as well as limitations in what is currently known using commercially available techniques.

Download references

Author information

Authors and Affiliations

  1. Lymphoma Program, Winship Cancer Institute/Emory University, 1365 Clifton Road, Atlanta, GA, 30322, USA

    Victor Orellana-Noia MD MSc & Aseala Abousaud PharmD BCOP

Authors
  1. Victor Orellana-Noia MD MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aseala Abousaud PharmD BCOP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor Orellana-Noia MD MSc.

Ethics declarations

Conflict of Interest

Victor Orellana-Noia has served as a consultant/advisory board member for ADC Therapeutics. Aseala Abousaud declares no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orellana-Noia, V., Abousaud, A. Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies. Curr. Treat. Options in Oncol. 23, 1443–1456 (2022). https://doi.org/10.1007/s11864-022-01017-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-022-01017-4

Keywords

Search

Navigation